-
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
INDIANAPOLIS , Aug. 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration ( FDA ) has approved Taltz ® (ixekizumab) injection 80 mg/mL f…
-
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
INDIANAPOLIS , Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pi…
-
Arbitration panel rules in favor of Lilly in complaint filed by Adocia
INDIANAPOLIS , Aug. 22, 2019 /PRNewswire/ -- A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY) in a claim filed by Adocia S.A. over the companies' prior collabo…
-
Lilly Announces Webcast to Discuss World Conference on Lung Cancer Presentation
INDIANAPOLIS , Aug. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at the 20…
-
Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health
INDIANAPOLIS , Aug. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pione…